Literature DB >> 33541272

Distributive characteristics of the CYP2C9 and AGTR1 genetic polymorphisms in Han Chinese hypertensive patients: a retrospective study.

Keping Chen1, Peng Xiao2, Guochun Li3, Chunling Wang2, Chuankun Yang2.   

Abstract

BACKGROUND: There is an individual variation in response to antihypertensive effect of the angiotensin II receptor antagonist. This study aimed to determine the allele and genotype frequencies of CYP2C9 and AGTR1 genetic polymorphisms and explore the potential role of these polymorphisms in guiding the selection of angiotensinIIreceptor antagonist in Han Chinese hypertensive patients.
METHODS: Totally 2419 Han Chinese hypertensive patients and 126 normotensive controls were recruited in this study. Venous blood samples were collected from each patient, and the genetic polymorphisms of CYP2C9 and AGTR1 were assessed using a gene chip platform. The allele and genotype frequency of each gene and the combined genotypes in this study were analyzed respectively.
RESULTS: The gene chip analysis identified an allelic frequency of 96.51% for CYP2C9*1 and 3.49% for CYP2C9*3 in the cohort of Han Chinese hypertensive patients. Statistical analysis showed that the frequency of wild-type homozygous for CYP2C9*1/*1 was 93.30%, while the frequency of heterozygous for *1/*3 or mutant homozygous for *3/*3 was 6.41% or 0.29%. Meanwhile, we detected allelic frequencies of 95.06% and 4.94% for the A and C allele of AGTR1, respectively. While the genotype frequency of wild-type homozygous for AA was 90.41%, the frequency of heterozygous for AC or mutant homozygous for CC was 9.30% or 0.29%. Notably, we observed that 84.66% (2048/2419) of the subjects exhibited a combined genotype of CYP2C9 and AGTR1 as *1/*1 + AA, while the combined genotypes *3/*3 + AC or *3/*3 + CC were not detected in hypertension patients. Besides, no significant association was found between normotensive controls and hypertensive patients, or among the three grades of hypertensive patients.
CONCLUSIONS: These data revealed the polymorphisms characteristics of CYP2C9 and AGTR1 in Han Chinese hypertensive patients, providing valuable information for genotype-based antihypertension therapy in prospective clinical studies in the future.

Entities:  

Keywords:  AGTR1; AngiotensinIIreceptor antagonist; CYP2C9; Genetic polymorphism; Hypertension

Year:  2021        PMID: 33541272      PMCID: PMC7863246          DOI: 10.1186/s12872-021-01895-w

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


  22 in total

1.  Evidence for involvement of 3'-untranslated region in determining angiotensin II receptor coupling specificity to G-protein.

Authors:  Thomas J Thekkumkara; Stuart L Linas
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

2.  CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population.

Authors:  Xiumei Hong; Shanchun Zhang; Guangyun Mao; Shanqun Jiang; Yan Zhang; Yunxian Yu; Genfu Tang; Houxun Xing; Xiping Xu
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

Review 3.  Antihypertensive pharmacogenetics: getting the right drug into the right patient.

Authors:  S T Turner; G L Schwartz; A B Chapman; W D Hall; E Boerwinkle
Journal:  J Hypertens       Date:  2001-01       Impact factor: 4.844

4.  Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese.

Authors:  Li He; Shaojun Chen; Jingao Li; Xiaoxue Xie; Lihua Huang; Yun Kuang; Kangwei Xu; Wanxia Huang; Yanling Zhao; Guoping Yang; Chengxian Guo
Journal:  Clin Exp Pharmacol Physiol       Date:  2020-06-16       Impact factor: 2.557

Review 5.  Pharmacogenetics of antihypertensive treatment.

Authors:  Donna K Arnett; Steven A Claas; Stephen P Glasser
Journal:  Vascul Pharmacol       Date:  2005-12-13       Impact factor: 5.773

6.  Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015.

Authors:  Zengwu Wang; Zuo Chen; Linfeng Zhang; Xin Wang; Guang Hao; Zugui Zhang; Lan Shao; Ye Tian; Ying Dong; Congyi Zheng; Jiali Wang; Manlu Zhu; William S Weintraub; Runlin Gao
Journal:  Circulation       Date:  2018-02-15       Impact factor: 29.690

7.  CYP2C9 genetic variants and losartan oxidation in a Turkish population.

Authors:  Melih O Babaoglu; Umit Yasar; Mia Sandberg; Erik Eliasson; Marja-Liisa Dahl; S Oguz Kayaalp; Atila Bozkurt
Journal:  Eur J Clin Pharmacol       Date:  2004-06-10       Impact factor: 2.953

8.  A1166C polymorphism of the angiotensin II type 1 receptor gene and essential hypertension in Han, Tibetan and Yi populations.

Authors:  Ying Liu; Ciren Zhuoma; Guangliang Shan; Chaoying Cui; Shuqin Hou; Weijun Qin; Dan Cai; Luobu Gesang; Zhansen Xiao; Zhaxi Pingcuo; Huaqing Zheng; Zhenglai Wu; Wenyu Zhou; Changchun Qiu
Journal:  Hypertens Res       Date:  2002-07       Impact factor: 3.872

9.  CYP2C9 allele variants in Chinese hypertension patients and healthy controls.

Authors:  Bang-ning Yu; Chen-Hui Luo; Dan Wang; An Wang; Zhi Li; Wei Zhang; Wei Mo; Hong-Hao Zhou
Journal:  Clin Chim Acta       Date:  2004-10       Impact factor: 3.786

Review 10.  Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.

Authors:  U I Schwarz
Journal:  Eur J Clin Invest       Date:  2003-11       Impact factor: 4.686

View more
  2 in total

1.  Association of AGTR1 A1166C and CYP2C9∗3 Gene Polymorphisms with the Antihypertensive Effect of Valsartan.

Authors:  Yi Liu; Xiaomu Kong; Yongwei Jiang; Meimei Zhao; Peng Gao; Xiao Cong; Yongtong Cao; Liang Ma
Journal:  Int J Hypertens       Date:  2022-03-19       Impact factor: 2.420

2.  Association of AGTR1 gene methylation and its genetic variant in Chinese farmer with hypertension: A case-control study.

Authors:  Zhi-Yuan Li; Qiang Ma; Xing Li; Shui-Yuan Yu; Juan Zuo; Chong-Jian Wang; Wen-Jie Li; Yue Ba; Fang-Fang Yu
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.